VERONA PHARMA PLC Inactive Instrument
Verona Pharma Plc Stock London S.E.
Equities
GB00B06GSH43
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 05-13 | HC Wainwright Adjusts Price Target on Verona Pharma to $30 From $32, Maintains Buy Rating | MT |
| 05-09 | Verona Pharma Signs Financing Agreements for Up to $650 Million | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 5.3M 6.72M 9.14M | Sales 2025 * | 75.71M 96.04M 131M | Capitalization | 893M 1.13B 1.54B |
|---|---|---|---|---|---|
| Net income 2024 * | -104M -132M -179M | Net income 2025 * | -65M -82.45M -112M | EV / Sales 2024 * | 134 x |
| Net cash position 2024 * | 184M 233M 317M | Net cash position 2025 * | 146M 186M 253M | EV / Sales 2025 * | 9.87 x |
| P/E ratio 2024 * |
-14.7
x | P/E ratio 2025 * |
-35
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Verona Pharma Plc
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +7.52% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.58% | 16.81B | |
| +37.41% | 12.54B | |
| -23.95% | 8.09B |
